Psychedelic Compound Composition for Depression Without Hallucinogenic Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for improved therapies for treating disorders such as depression, anxiety, and headache that can be synthesized as small-molecule compounds with enhanced efficacy while avoiding the drawbacks of existing treatments.
Innovation Solution
Development of compounds with specific structures, including Formulae (I), (Ia), (Ib), (II), and (III), which can form pharmaceutically acceptable salts or esters, and are administered in pharmaceutical compositions to treat disorders like anxiety, depression, and headache.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If LSD is used to treat depression and anxiety, then therapeutic effects are achieved, but adverse psychiatric reactions and hallucinogen persisting perception disorder occur
Solution Approach 1:
The patent uses 2-bromo-LSD as an intermediary substance that blocks the 5-HT2A receptor to prevent adverse effects of LSD, while co-administering LSD or its analogs to provide therapeutic benefits. This intermediary approach allows decoupling of therapeutic effects from harmful side effects by using a blocking agent that selectively prevents pathological reactions without eliminating beneficial outcomes.
Solution Approach 2:
The patent modifies the chemical structure of LSD by introducing bromine substitution at the 2-position to create 2-bromo-LSD, which changes the pharmacological parameters of the compound. This structural modification transforms the drug's properties from producing hallucinogenic effects to selectively blocking 5-HT2A receptors, thereby changing the therapeutic window and reducing adverse effects while maintaining antidepressant and anxiolytic properties.
2Reliability
If conventional antidepressants are used, then depression is treated, but efficacy is limited and side effects occur
Solution Approach 1:
The patent employs compounds with modified chemical structures (2-bromo-LSD and analogs) that change the pharmacological parameters compared to conventional antidepressants. These structural modifications enable selective 5-HT2A receptor blockade with enhanced antidepressant and anxiolytic efficacy, overcoming the limited effectiveness of traditional antidepressant mechanisms.
3Power
If high doses of LSD are used to achieve therapeutic effects, then treatment potency increases, but adverse effects and duration of action increase
Solution Approach 1:
The patent achieves high treatment potency through structural modification of LSD to create 2-bromo-LSD and related analogs. These compounds exhibit enhanced potency with lower effective doses, changing the dose-response parameters to provide therapeutic benefits at reduced concentrations, thereby minimizing adverse effects while maintaining or improving treatment power.
Data Source
AI summary
In some aspects, pharmaceutical compounds are disclosed which may be useful for treating anxiety and/or other disorders. In another aspect, a pharmaceutical composition includes a therapeutically effective amount of the compound(s) and a pharmaceutically acceptable vehicle therefor. In yet another aspect, a method of treating anxiety, depression, obsessive-compulsive disorder, tobacco addiction, alcohol addiction, cocaine addiction, headache, cluster headache, or cancer-related or other end-of-life psychological distress involves administering the pharmaceutical composition to an individual in need thereof.